Insight Molecular Diagnostics Net Change in Long-Term Investments 2014-2025 | IMDX
Insight Molecular Diagnostics net change in long-term investments from 2014 to 2025. Net change in long-term investments can be defined as the net cash flows from the sale and purchase of investments with maturities greater than one year.
| Insight Molecular Diagnostics Annual Net Change in Long-Term Investments (Millions of US $) |
|
|---|---|
| 2024 | $N/A |
| 2023 | $N/A |
| 2022 | $N/A |
| 2021 | $N/A |
| 2020 | $-4 |
| 2019 | $-11 |
| 2018 | $N/A |
| 2017 | $N/A |
| 2016 | $N/A |
| 2015 | $1 |
| 2014 | $N/A |
| 2013 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.087B | $0.002B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $46.182B | 58.76 |
| Doximity (DOCS) | United States | $11.140B | 51.57 |
| Hims & Hers Health (HIMS) | United States | $10.623B | 110.37 |
| Tempus AI (TEM) | United States | $10.245B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $4.558B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.855B | 60.24 |
| Hinge Health (HNGE) | United States | $3.480B | 0.00 |
| Privia Health (PRVA) | United States | $2.672B | 182.67 |
| Enovis (ENOV) | United States | $1.911B | 10.66 |
| Phreesia (PHR) | United States | $1.730B | 0.00 |
| 10x Genomics (TXG) | United States | $1.602B | 0.00 |
| Schrodinger (SDGR) | United States | $1.538B | 0.00 |
| Azenta (AZTA) | United States | $1.504B | 69.89 |
| Omnicell (OMCL) | United States | $1.396B | 24.63 |
| Evolent Health (EVH) | United States | $1.377B | 117.30 |
| Clover Health Investments (CLOV) | United States | $1.318B | 0.00 |
| Claritev (CTEV) | United States | $0.699B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.612B | 0.00 |
| Veradigm (MDRX) | United States | $0.525B | 0.00 |
| Standard BioTools (LAB) | United States | $0.520B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.485B | 0.00 |
| Talkspace (TALK) | United States | $0.440B | 131.50 |
| Outset Medical (OM) | United States | $0.365B | 0.00 |
| TruBridge (TBRG) | United States | $0.340B | 755.33 |
| Health Catalyst (HCAT) | United States | $0.283B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.262B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.203B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.168B | 0.00 |
| American Well (AMWL) | United States | $0.134B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.131B | 0.00 |
| Pulmonx (LUNG) | United States | $0.110B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.104B | 0.00 |
| CareCloud (CCLD) | United States | $0.104B | 3.95 |
| 111 (YI) | China | $0.063B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.049B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.048B | 0.00 |
| HeartBeam (BEAT) | United States | $0.044B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.040B | 0.00 |
| Zhongchao (ZCMD) | China | $0.030B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Precipio (PRPO) | United States | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.015B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.011B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.010B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.009B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.007B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |